Group 1 - The long-term potential of China's healthcare market remains optimistic, but the pharmaceutical sector has surged 64% this year due to licensing optimism, leading to a shift in market focus towards organic revenue/profit growth due to rising risks from potential U.S. executive orders and high valuations [1][2] - UBS downgraded the ratings of CSPC Pharmaceutical Group (01093) and Kelun Pharmaceutical (002422.SZ) to "Neutral" based on weak fundamentals, while changing its industry preference from 3SBio (01530) to Hansoh Pharmaceutical (03692) due to its stable traditional business and innovative pipeline [1] - The report indicates that the forward P/E ratio of Chinese pharmaceutical stocks is above the five-year average, with increasing risks from U.S. executive orders shifting market focus back to organic growth [1] Group 2 - CSPC's core traditional product NBP, which accounts for 32% of its 2024 finished drug revenue, continues to lose market share, and its high dependence on unconfirmed business development revenue increases uncertainty [2] - Kelun Pharmaceutical faces weak demand and intense competition, which may result in the lowest revenue growth among peers by 2025 [2] - The expected compound annual growth rate (CAGR) for CSPC and Kelun from 2024 to 2034 is only half of the average 13% CAGR of 3SBio, Hansoh, and Innovent Biologics [1]

Core Viewpoint - UBS maintains an optimistic outlook on the long-term potential of China's healthcare market, but due to a 64% increase in the pharmaceutical sector driven by licensing optimism, along with rising risks from potential U.S. executive orders and high valuations, the market focus is expected to shift back to organic revenue/profit growth [1] Company Ratings - The ratings for CSPC Pharmaceutical Group (01093) and Kelun Pharmaceutical (002422) have been downgraded to "Neutral" due to weak fundamentals [1] - The preferred stock in the industry has shifted from 3SBio (01530) to Hansoh Pharmaceutical (03692) because of its stable traditional business and innovative pipeline reserves [1] Long-term Pipeline Potential - The report indicates that the best performers in terms of long-term pipeline potential are Hengrui Medicine (600276) and Hansoh Pharmaceutical [1] Valuation and Market Focus - Chinese pharmaceutical stocks have a forward P/E ratio higher than the five-year average, but the rising risk of U.S. executive orders is shifting market focus back to organic growth [1] - CSPC and Kelun are expected to have the lowest compound annual growth rate (CAGR) in revenue from 2024 to 2034, at half the average rate of 13% for 3SBio, Hansoh, and Innovent Biologics [1] Company-Specific Challenges - CSPC's core traditional product NBP, which accounts for 32% of its 2024 finished drug revenue, continues to lose market share, increasing uncertainty due to high reliance on unconfirmed business development revenue [1] - Kelun Pharmaceutical faces weak demand and intense competition, which may lead to the lowest revenue growth among peers by 2025 [1]

Group 1 - UBS maintains a positive outlook on the long-term potential of China's healthcare market, but notes a 64% increase in the pharmaceutical sector this year due to optimistic sentiment from licensing agreements, alongside rising risks from potential U.S. executive orders and high valuations [1] - The focus is expected to shift back to organic revenue/profit growth due to weak fundamentals, leading to downgrades for CSPC Pharmaceutical Group and Kelun Pharmaceutical to "Neutral" [1] - UBS has changed its preferred stock in the industry from 3SBio to Hansoh Pharmaceutical, citing Hansoh's stable traditional business and innovative pipeline reserves [1] Group 2 - The report indicates that the forward P/E ratio of Chinese pharmaceutical stocks is above the five-year average, with rising risks from U.S. executive orders shifting market focus back to organic growth [1] - CSPC and Kelun are projected to have the lowest compound annual growth rate (CAGR) for revenue from 2024 to 2034, at half the average of 13% for peers like 3SBio, Hansoh, and Innovent Biologics [1] - CSPC's core traditional product NBP, which accounts for 32% of its 2024 finished drug revenue, continues to lose market share, increasing uncertainty due to high reliance on unconfirmed business development revenue [1] - Kelun faces weak demand and intense competition, which may result in the lowest revenue growth among peers by 2025 [1]

Investment Rating - The industry investment rating is "Outperform" [1] Core Insights - The report highlights that the recent tariff announcement by the U.S. government is expected to have a minimal impact on the pharmaceutical sector, suggesting that the current market downturn presents a good opportunity to increase positions in innovative drugs [4][13] - The report emphasizes the ongoing adjustments in the innovative drug sector, indicating that the recent price corrections are largely complete, and recommends maintaining or increasing exposure to high-quality stocks with growth potential [7][17] - The report discusses the positive outlook for the medical device sector due to new procurement policies aimed at preventing price wars, which could benefit companies previously affected by valuation pressures [8][23] Summary by Sections Industry Overview - The closing index for the pharmaceutical sector is 8770.86, with a weekly high of 9323.49 and a low of 6764.34 [1] Market Performance - For the week of September 22-26, 2025, the A-share pharmaceutical sector fell by 2.2%, underperforming the CSI 300 index by 3.27 percentage points and the ChiNext index by 4.16 percentage points [6][14][32] - The report ranks the pharmaceutical sector 26th among 31 first-level sub-industries in terms of weekly performance [14] Innovative Drugs - The innovative drug sector is experiencing a correction, with a recommendation to focus on high-quality stocks with growth potential, including companies like Innovent Biologics and Hengrui Medicine [7][17] Medical Devices - The National Healthcare Security Administration's new procurement policies are expected to positively impact the medical device sector, particularly benefiting companies like Mindray and Aohua [8][23] CDMO and CRO Sectors - The report expresses optimism about the CDMO sector's recovery, driven by increasing overseas demand and the upcoming interest rate cuts in the U.S. [18] - The CRO sector is also expected to see improved performance as domestic innovative drug demand stabilizes [18][19] Research Services - The report indicates a potential turnaround in the research services sector, with a focus on companies with strong competitive advantages [21] Biologics - The report notes that the blood products sector is currently facing downward pressure, while the vaccine sector is struggling due to declining birth rates and market saturation [22] Medical Services - The report highlights the potential for growth in the medical services sector, particularly for companies expanding their market share through acquisitions [26][27] Traditional Chinese Medicine - The report suggests that companies involved in innovative research and those benefiting from procurement policies are likely to see growth [28] Pharmaceutical Commerce - The report anticipates increased concentration in the retail pharmacy sector, with leading companies expected to gain market share [30][31]

Core Insights - Tai Chi Group's subsidiary Southwest Pharmaceutical has had its application for the generic version of Atomoxetine Hydrochloride Capsules accepted, with the original product set to cease supply in the Chinese market by January 2024 [1][2] - Atomoxetine, originally developed by Eli Lilly, is a non-stimulant medication recommended for treating ADHD in children and adolescents, with significant sales growth in the Chinese market [2][4] Company Developments - Southwest Pharmaceutical is currently the only company actively pursuing a 4th category new registration for the generic version of Atomoxetine Hydrochloride Capsules [4] - The company has increased its investment in the neuropsychiatric drug sector, with total R&D expenditure rising from 14.6 million to 28.2 million yuan from 2021 to 2024, representing an increase in revenue proportion from 1.20% to 2.28% [13][15] Market Context - The total sales of neuropsychiatric drugs in the hospital market are projected to exceed 110 billion yuan in 2024, with major market players including Renfu (21.31% market share), Shiyao Group (16.8%), and Yangtze River Pharmaceutical (approximately 13%) [4] - In 2021, the sales of Atomoxetine Hydrochloride Capsules in the full-terminal hospital market surpassed 300 million yuan, reflecting a year-on-year growth rate of 46.64% [2][4]

Core Viewpoint - Tianfeng Securities maintains a "Buy" rating for Shiyao Group, forecasting revenue and net profit growth from 2025 to 2027 despite a decline in 2025H1 performance due to comprehensive procurement execution and pressure on traditional medicine sales [1] Group 1: Financial Performance - In 2025H1, the company reported revenue of 13.273 billion yuan, a year-on-year decrease of 18.5%, and a net profit of 2.548 billion yuan, down 15.6% [1] - The traditional medicine business revenue was 10.248 billion yuan, including 1.075 billion yuan from licensing income, representing a year-on-year decline of 24.4% [2] - Excluding licensing income, product sales revenue fell by 32.3%, with significant declines in various therapeutic areas [1][2] Group 2: Licensing Income and Business Development - Licensing income has become a strong source of revenue and profit for the company, with a 120 million USD upfront payment for SYH2086 expected to contribute to future income [2] - The company has successfully executed six business development projects in 2024, highlighting the value of its eight R&D platforms [2] Group 3: Clinical Developments and Drug Approvals - SYS6010 has initiated overseas Phase III clinical trials, with positive early data recognized by regulatory authorities in both China and the U.S. [2] - The first domestic HER2 bispecific antibody, KN026, has had its new drug application accepted by the Chinese National Medical Products Administration, showing promising clinical trial results [3] - Multiple clinical data readouts are expected in 2025, with several ongoing trials across various cancer types [4]

Core Viewpoint - Tianfeng Securities maintains a "buy" rating for Shiyao Group (01093), forecasting revenue and net profit growth from 2025 to 2027 despite a decline in 2025H1 due to pressure from centralized procurement and a significant drop in traditional drug sales [1] Group 1: Financial Performance - In 2025H1, the company reported revenue of 13.273 billion yuan, a year-on-year decrease of 18.5%, and a net profit of 2.548 billion yuan, down 15.6% [1] - The traditional drug business saw a revenue drop of 24.4% to 10.248 billion yuan, with product sales declining by 32.3% when excluding authorized income [1] Group 2: Business Segments - Authorized income has become a significant source of revenue and profit for the company, with a 120 million USD upfront payment for SYH2086 expected to contribute to future earnings [2] - The company has established six business development (BD) projects in 2024, highlighting the value of its eight R&D platforms [2] Group 3: Clinical Developments - SYS6010 has initiated overseas Phase III clinical trials, with positive early data recognized by regulatory authorities in both China and the U.S. [3] - The HER2 bispecific antibody KN026 has had its new drug application accepted by the Chinese National Medical Products Administration, showing promising clinical trial results [4] - Multiple clinical data readouts are expected in 2025, including various ongoing trials for different cancer treatments [5]

Core Insights - The top three companies by Hong Kong Stock Connect holding ratios are COSCO Shipping Energy (70.65%), China Telecom (70.49%), and Yangtze Optical Fibre and Cable (70.24%) [1] - Alibaba (W) saw the largest increase in holding amount over the last five trading days, with an increase of 9.659 billion yuan, followed by Tencent Holdings with 2.552 billion yuan, and SMIC with 1.472 billion yuan [1] - The companies with the largest decrease in holding amounts over the same period include Pop Mart (-0.976 billion yuan), CSPC Pharmaceutical (-0.594 billion yuan), and Hang Seng China Enterprises (-0.560 billion yuan) [1] Group 1: Top Holding Ratios - COSCO Shipping Energy (01138) has a holding ratio of 70.65% with 916 million shares [1] - China Telecom (00728) has a holding ratio of 70.49% with 9.784 billion shares [1] - Yangtze Optical Fibre and Cable (06869) has a holding ratio of 70.24% with 247 million shares [1] Group 2: Recent Increases in Holdings - Alibaba (W) (09988) increased its holding amount by 9.659 billion yuan, with a change of 58.0117 million shares [1] - Tencent Holdings (00700) increased its holding amount by 2.552 billion yuan, with a change of 3.9628 million shares [1] - SMIC (00981) increased its holding amount by 1.472 billion yuan, with a change of 2.0176 million shares [1] Group 3: Recent Decreases in Holdings - Pop Mart (09992) decreased its holding amount by 0.976 billion yuan, with a change of -3.6698 million shares [3] - CSPC Pharmaceutical (01093) decreased its holding amount by 0.594 billion yuan, with a change of -6.5368 million shares [3] - Hang Seng China Enterprises (02828) decreased its holding amount by 0.560 billion yuan, with a change of -589,320 shares [3]

Group 1 - The report highlights the calendar effect on market performance before and after the National Day holiday from 2010 to 2024, indicating a median return of -0.81% in the five trading days before the holiday and a strong median return of 2.27% in the first five trading days after the holiday, with an overall median increase of 2.28% over the following 20 trading days [2][28][29] - Domestic industrial profits saw a significant year-on-year increase in August, with the cumulative year-on-year growth turning positive, and marginal increases in profit margins for mining, manufacturing, and public utilities [2][30] - Internationally, the core PCE growth rate in the US for August met expectations at 2.9%, with a high probability of a 25 basis point rate cut by the Federal Reserve in October 2025 [2][31] Group 2 - The report discusses the importance of lithography machines in the semiconductor industry, emphasizing their role as the most significant category of semiconductor equipment and the continuous development opportunities driven by semiconductor demand [4][33] - The report notes that the semiconductor sector showed strong performance during the week of September 22-26, with an average daily trading volume of 23,092 billion yuan, despite a slight decrease from the previous week [4][34] - Key themes include the domestic validation of lithography machines by SMIC, the high demand for AI and robotics, and the emergence of humanoid robots marking a new era in the industry [4][34][37] Group 3 - The report outlines the "以存代算" (compute by storage) paradigm in AI storage, highlighting its significance in AI inference and the hardware breakthroughs that allow SSDs to participate as core components in AI processing [10] - The report identifies several companies actively involved in the "以存代算" space, including Huawei and Inspur, which are developing products that optimize storage architecture and cache management [10] - The report indicates that the demand for SSDs is expected to grow faster than traditional curves due to the AI storage revolution [10] Group 4 - The report discusses the potential of planetary roller screws in automotive applications, particularly in brake systems and steering systems, highlighting their advantages over traditional technologies [11] - The market share of foreign manufacturers in the planetary roller screw market exceeded 60% in 2022, with Swiss company GSA/Rollvis holding a dominant position [11] - The report anticipates a gradual increase in the market penetration of rear-wheel steering technology using planetary roller screws from 2025 to 2030 [11] Group 5 - The report emphasizes the release of the "Stabilization and Growth Work Plan for the Petrochemical Industry" by multiple ministries, which aims to optimize the industry structure and promote high-quality development [20] - The report suggests that the petrochemical sector is transitioning from a focus on expansion to optimizing existing capacities and pursuing high-quality growth opportunities [20] - The report indicates that the chemical sector is expected to benefit from price recovery cycles and the emergence of new high-end materials [20]

Core Viewpoint - The surge in A-share and Hong Kong stock prices of innovative drug companies is driven by potential business development (BD) expectations, particularly for those seen as acquisition targets by multinational pharmaceutical companies [2][3] Group 1: Business Development Trends - Pfizer's recent $7.3 billion acquisition of Metsera signals a significant return to the weight-loss drug market, impacting domestic stock prices of related companies [2] - Global pharmaceutical transactions have increased from 358 in 2015 to 743 in 2024, with a compound annual growth rate of 8%, while China's transactions surged from 55 to 213, with total values rising from $3.1 billion to $57.1 billion [3] - Major Chinese companies like 3SBio, CSPC, and Hengrui have secured BD deals exceeding $5 billion this year, with Hengrui's $12.5 billion agreement with GSK setting a record for Chinese innovative drug exports [3] Group 2: Market Sentiment and Investor Behavior - Investors are becoming more discerning, focusing on the specifics of BD deals, such as upfront payment ratios and the long-term capabilities of partners, rather than merely the announcement of negotiations [4] - There is a growing concern that many top buyers have already completed their acquisitions, leading to potential valuation declines and tougher negotiations for remaining assets [4][5] - Past instances show that underwhelming BD deals can lead to significant stock price declines, as seen with Rongchang Bio and Hengrui [5] Group 3: Future Opportunities and Market Dynamics - Despite concerns about a potential slowdown in BD activity, industry leaders assert that opportunities continue to emerge, particularly as multinational companies adjust their R&D strategies every 5 to 10 years [7] - The demand for innovative assets remains strong, with a shift towards ADCs and bispecific antibodies, indicating a recognition of Chinese companies' R&D capabilities [8][9] - The trend of multinational companies seeking earlier-stage projects reflects a strategic shift towards building comprehensive product portfolios, as seen in Pfizer's acquisition of Metsera, which enhances its offerings in the GLP-1 space [9]